Axogen/AXGN

$6.86

5.53%
-
1D1W1MYTD1YMAX

About Axogen

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.

Ticker

AXGN

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Karen Zaderej

Employees

426

Headquarters

Alachua, United States

Axogen Metrics

BasicAdvanced
$280.84M
Market cap
-
P/E ratio
-$0.51
EPS
1.06
Beta
-
Dividend rate
$280.84M
1.06088
$10.83
$3.45
397.41K
2.892
2.136
48.735
48.741
-11.07%
-22.08%
-12.85%
1.766
2.93
3.082
14.74%
26.42%
12.29%

What the Analysts think about Axogen

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
99.27% upside
High $17.00
Low $11.00
$6.86
Current price
$13.67
Average price target

Axogen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-8.85% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$42.9M
4.13%
Net income
$-3.8M
-5%
Profit margin
-8.85%
-8.76%

Axogen Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 37.82%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.10
-$0.03
$0.01
-$0.06
-
Expected
-$0.15
-$0.13
-$0.06
-$0.10
-$0.07
Surprise
-31.03%
-76.92%
-116%
-37.82%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Axogen stock?

Axogen (AXGN) has a market cap of $280.84M as of April 23, 2024.

What is the P/E ratio for Axogen stock?

The price to earnings (P/E) ratio for Axogen (AXGN) stock is 0 as of April 23, 2024.

Does Axogen stock pay dividends?

No, Axogen (AXGN) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Axogen dividend payment date?

Axogen (AXGN) stock does not pay dividends to its shareholders.

What is the beta indicator for Axogen?

Axogen (AXGN) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Axogen stock price target?

The target price for Axogen (AXGN) stock is $13.67, which is 99.27% above the current price of $6.86. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Axogen stock

Buy or sell Axogen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing